Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain

Schizophrenia Research

Volumn 73, Issue 2-3, 2005, Pages 147-152

  Reynolds, Lindsay M ^a   Cochran, Susan M ^b   Morris, Brian J ^b   Pratt, Judith A ^b   Reynolds, Gavin P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

N acetylaspartate (NAA); N acetylaspartylglutamate (NAAG); N methyl D aspartate (NMDA) receptor; Phencyclidine (PCP); Rat; Schizophrenia

Indexed keywords

N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PHENCYCLIDINE;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TEMPORAL CORTEX;

ANIMALS; ASPARTIC ACID; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FRONTAL LOBE; HALLUCINOGENS; HIPPOCAMPUS; MALE; PHENCYCLIDINE; PSYCHOTIC DISORDERS; RATS; RATS, LONG-EVANS; TEMPORAL LOBE;

EID: 11844305557     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.02.003     Document Type: Article

References (38)

1. Abdul-Monim Z., Neill J.C., Reynolds G.P. Sub-chronic PCP administration significantly alters parvalbumin-immunoreactive interneurones in the prefrontal cortex and hippocampus of the rat. Br. Neurosci. Assoc. Abstr. 17:2003;103
2. Allen R.M., Young S.J. Phencylidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1084
3. Anderson K.J., Monaghan D.T., Cangro C.B., Namboodiri M.A.A., Neale J.H., Beasley C.L., Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24:1997;349-355
4. Beasley C.L., Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24:1997;349-355
5. Bertolino A., Callicott J.H., Elman I., Mattay V.S., Tedeschi G., Frank J.A., Breier A., Weinberger D.R. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry. 43:1998;641-648
6. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., Weinberger D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry. 49:2001;39-46
7. Cecil K.M., Lenkinski R.E., Gur R.E., Gur R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology. 20:1999;131-140
8. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology. 28:2003;265-275
9. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., Olney J.W. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752:1997;1-14
10. Crow T.J. Constraints on concepts of pathogenesis. Language and the speciation process as the key to the etiology of schizophrenia. Arch. Gen. Psychiatry. 52:1995;1011-1014
11. Danos P., Baumann B., Bernstsin H.G., Franz M., Stauch R., Northoff G., Krell D., Deicken R.F., Johnson C., Pegues M. Proton magnetic resonance spectroscopy of the human brain in schizophrenia. Rev. Neurosci. 11:2000;147-158
12. Flores C., Coyle J.T. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology. 28:2003;1227-1234
13. Forloni G., Grzanna R., Blakely R.D., Coyle J.T. Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse. 1:1987;455-460
14. Fukuzako H., Takeuchi K., Hokazono Y., Fukuzako T., Yamada K., Hashiguchi T., Obo Y., Ueyama K., Takigawa M., Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res. 61:1995;193-200
15. Grunze H., Rainnie D., Hearn E., Barkai E., Hasselmo M., McCarley R., Greene R. Impaired LTP of recurrent inhibition onto hippocampal pyramidal cells: a possible cellular basis of schizophrenia. Schizophr. Res. 15:1995;28-29
16. Henn F.A. The NMDA receptor as a site for psychopathology. Primary or secondary role? Arch. Gen. Psychiatry. 52:1995;1008-1010
17. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308
18. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
19. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955
20. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99
21. Luby E.D., Cohen C.B., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenomimetic drug - Serynl. Arch. Neurol. Psychiatry. 81:1959;363-369
22. Neale J.H., Bzdega T., Wroblewska B. N-acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 75:2000;443-452
23. Nudmamud S., Reynolds L.M., Reynolds G.P. N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder. Biol. Psychiatry. 53:2003;1138-1141
24. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362
25. Olney J.W., Farber N.B., Nuri B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007
26. Omori M., Pearce J., Komoroski R.A., Griffin W.S., Mrak R.E., Husain M.M., Karson C.N. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol. Psychiatry. 42:1997;359-366
27. O'Neill J., Eberling J.L., Schuff N., Jagust W., Reed B., Soto G., Ezekiel F., Klein G., Weiner M.W. Method to correlate 1H MRSI and 18FDG-PET. Magn. Reson. Med. 43:2000;244-250
28. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol. 31:1997;97-118
29. Passani L.A., Vonsattel J.P., Coyle J.T. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 772:1997;9-22
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1998;Academic Press, San Diego
31. Pearlson G.D., Marsh L. Structural brain imaging in schizophrenia: a selective review. Biol. Psychiatry. 46:1999;627-649
32. Rowland L., Bustillo J.R., Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry. 6:2001;121-130
33. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry. 49:1992;522-530
34. Trombley P.Q., Westbrook G.L. Excitatory synaptic transmission in cultures of rat olfactory bulb. J. Neurophysiol. 64:1990;598-606
35. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry. 52:1995;829-836
36. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., Berman K.F., Goldberg T.E. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry. 50:2001;825-844
37. Westbrook G.L., Mayer M.L., Namboodiri M.A., Neale J.H. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci. 6:1986;3385-3392
38. Wolkin A., Sanfilipo M., Wolf A.P., Angrist B., Brodie J.D., Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch. Gen. Psychiatry. 49:1992;959-965